Results

Total Results: 515 records

Showing results for "renal".

101. Dialysis | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/dialysis
     January 24, 2012 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal … Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage Renal

102. CER 220 Evidence Summary: Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-220-analgesics-acute-pain-summary.pdf
     September 01, 2019 - Comparison of intranasal ketamine versus IV morphine in reducing pain in patients with renal colic. … Can low-dose of ketamine reduce the need for morphine in renal colic? … Delivering safe and effective analgesia for management of renal colic in the emergency department: … Comparison of IV dexketoprofen trometamol, fentanyl, and paracetamol in the treatment of renal colic … Intravenous paracetamol vs ibuprofen in renal colic: a randomised, double-blind, controlled clinical

103. The Effect of Protein Intake on Health (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/effect-protein-intake-protocol-amendment.pdf
     November 29, 2023 - Renal haemodynamic responses to a chicken or beef meal in normal individuals. … Dietary protein intake and renal function. Nutr Metab (Lond). … Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig. … or ureterolithiasis or renal calculi or renal disease? … or renal function or renal insufficiency).ti,ab. 426914 4 Muscular Atrophy/ or exp Muscle Strength/

104. Management of Gout | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/gout/research-protocol
     March 01, 2020 - (XOIs- allopurinol and febuxostat) to reduce sUA production; uricosurics probenecid, which prevents renal … differ according to patient baseline demographic characteristics and co-morbid conditions (including renal … -5) Patients with comorbidities, including hypertension, Type 2 diabetes, chronic kidney disease (renal … daily living (ADLs) Patient global assessment Recurrence Safety Gastrointestinal and renal … conducted by age group; particular comorbidities, such as patients with hypertension, type 2 DM, or renal

105. Executive Summary: Pain Management Interventions for Hip Fracture (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/cer30_hip-fracture-pain-executive-summary_20110517.pdf
     May 01, 2011 - mortality (30­day), and the incidence of serious adverse effects (e.g., delirium, myocardial infarction, renal … Myocardial infarction Spinal vs. general anesthesia Insufficient No significant difference (2 RCT) Renal … difference standard spinal anesthesia (1 RCT) Myocardial infarction None Insufficient No data Renal … Multimodal pain management Insufficient No significant difference vs. standard care (1 cohort study) Renal … Stroke Nerve block vs. no nerve block Insufficient No significant difference (1 RCT, 1 cohort study) Renal

106. Vte-Prophyalaxis Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/vte-prophyalaxis_executive.pdf
     May 01, 2013 - failure, chronic renal failure, or end-stage renal disease. 22-25 Some of these patient groups have … impairment, or severe renal impairment not undergoing dialysis and patients receiving dialysis? … impairment, severe renal impairment, and renal replacement therapy (KQ 8) Special Populations (Timing … impairment, severe renal impairment, renal replacement therapy • Animal studies/models • Children … CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency.

107. Iron | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/iron
     January 14, 2013 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal … Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage Renal

108. Evidence-Summary-CER-206-Sodium-And-Potassium-Intake-Effects-On-Chronic-Disease-Outcomes-And-Risk (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-206-evidence-summary-sodium-potassium.pdf
     June 01, 2018 - Among subpopulations defined by hypertension, diabetes, obesity, and renal health status. … Among subpopulations defined by hypertension, diabetes, obesity, and renal health status. … Among subpopulations defined by hypertension, diabetes, obesity, and renal health status. … Among subpopulations defined by hypertension, diabetes, obesity, and renal health status. … Among subpopulations defined by hypertension, diabetes, obesity, and renal health status.

109. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia-2011_research-protocol.pdf
     January 01, 2011 - According to the United States Renal Data System, 67.4 percent of patients initiating dialysis had … Prevalence and management of anemia in renal transplant recipients: a European survey. … United States Renal Data System. 2010 USRDS Annual Data Report: Vol. 2 Atlas of End-Stage Renal Disease … The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. … CMS proposes new prospective payment system for renal dialysis facilities [press release].

110. Vascular Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/vascular-diseases?page=4
     December 02, 2008 - Review Archived November 19, 2007 Comparative Effectiveness of Management Strategies for Renal … Systematic Review Archived October 24, 2006 Comparative Effectiveness of Management Strategies for Renal

111. Anemia | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/anemia
     October 12, 2012 - Comparative Effectiveness of Intravenous Iron Formulations in the Treatment of Anemia in End Stage Renal … Effectiveness Research to Improve Anemia Management and Cardiovascular Disease Outcomes in End-Stage Renal

112. The Effect of Protein Intake on Health | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/effect-protein-intake/protocol
     December 01, 2023 - Renal haemodynamic responses to a chicken or beef meal in normal individuals. … Dietary protein intake and renal function. Nutr Metab (Lond). … Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig. … or ureterolithiasis or renal calculi or renal disease? … or renal function or renal insufficiency).ti,ab.           426914 4          Muscular Atrophy/ or exp

113. Calcineurin_Inhibitors_Protocol_FINAL_10-07-2014 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/calcineurin-inhibitor_research-protocol.pdf
     October 08, 2014 - almost 60% of all organ transplants.1 Kidney transplantation is the treatment of choice for end stage renal … Cyclosporine and tacrolimus are the most commonly used CNIs in renal transplant recipients during the … Long term renal allograft survival in the United States: a critical reappraisal. … Reduced exposure to calcineurin inhibitors in renal transplantation. … graft dysfunction'/exp OR 'renal graft dysfunction' OR (kidney OR renal) NEAR/2 (allograft* OR alograft

114. Gout-managment-protocol-141103 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/gout_research-protocol.pdf
     November 03, 2014 - Hyperuricemia can be the result of either inadequate renal excretion of UA or, less commonly, UA overproduction … XOIs- allopurinol and febuxostat) to reduce sUA production; uricosurics probenecid, which prevents renal … differ according to patient baseline demographic characteristics and co-morbid conditions (including renal … • Patients with comorbidities, including hypertension, Type 2 diabetes, chronic kidney disease (renal … conducted by age group; particular comorbidities, such as patients with hypertension, type 2 DM, or renal

115. Comparative Effectiveness Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
     January 01, 2006 - Osteoarthritis; Acute shoulder pain; Fever OA and RA: 1,500 mg 2x/day or 3,000 mg 1x/day Renal … in 2-3 doses; Extended- release, 100-200 mg/day RA: Delayed- release, 100-200 mg/day in 3- 4 Renal … impairment(CrCl >25 mL/min) max 150 mg/day; Moderate renal impairment (CrCl l<25 mL/min) max 100 … Elderly – 4.3 to 7.6 hours; Hepatic dysfunction – 1.6 to 7.6 hours; Renal impairment – 3.4 to 18.9 … : No SS difference b/t lumiracoxib and NSAIDs for renal endpoint or serious liver AEs.

116. Heart Diseases | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/heart-diseases?page=4
     October 16, 2009 - Review Archived November 19, 2007 Comparative Effectiveness of Management Strategies for Renal … Systematic Review Archived October 24, 2006 Comparative Effectiveness of Management Strategies for Renal

117. Surgery | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/surgery?page=5
     June 28, 2010 - Review Archived November 19, 2007 Comparative Effectiveness of Management Strategies for Renal … Systematic Review Archived October 24, 2006 Comparative Effectiveness of Management Strategies for Renal

118. Methods Research Report - Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/survival-quality_research.pdf
     April 01, 2013 - Mohamed et al.,40 evaluated the benefit-risk preferences of patients with renal cell carcinoma, using … Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. … Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. … " [Supplementary Concept] OR sunitinib OR sutent) AND ("Carcinoma, Renal Cell"[Mesh] OR "renal cell … Sorafenib in advanced clear-cell renal-cell carcinoma.

119. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - gout purportedly have insufficient excretion of uric acid, which could be due to genetic defects in renal … organic anion transporter involved in controlling the reabsorption of uric acid from the proximal renal … Monotherapy lesinurad resulted in more patients experiencing elevated serum creatinine levels and renal … However, better gout management could reduce hospitalizations and renal or cardiovascular complications … also provide cost offsets from treatment with lesinurad.18 One research expert noted concerns over renal

120. Effective Health Care (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0320_06-17-2009.pdf
     January 01, 2009 - associated with these diseases (i.e., bone issues, elevated urine/serum protein, anemia, fatigue, or renal … What are the day-to-day biological variables, such as renal function, that affect the utility of FLC